Bioasis Technologies Inc. V.BTI

Edison Group on Midatech:

[prophetoffactz]

November 15 update:


Preliminary glioblastoma data in the first half of 2023 is a key catalyst.

"The study will use the same single-catheter CED system used in the first Phase I study in diffuse intrinsic pontine gliomas (DIPG), which reported encouraging headline data in October 2020. We also note that the FDA granted the fast-track designation to MTX110 in rGBM in June 2022 allowing Midatech to apply for expedited approval and a potentially faster market entry, provided supportive Phase II data are obtained."

"Previously, Midatech reported H122 results, which reiterated its focus on expanding its core Q-Sphera technology portfolio and leading MTX110 into the clinic in rGBM. Following expansion of the R&D collaboration agreement with Janssen for encapsulation of its experimental monoclonal antibody, the company is working on developing methods for encapsulation of bispecific T cell engager molecules and antibody-drug conjugates, both of which have shown utility in oncology and present considerable market opportunity. In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University.

We see partnership and licensing discussions possibly regaining momentum with clinical traction, which could potentially crystallise into a deal on the back of positive proof-of-concept or Phase II readouts. Preliminary data from the Phase I DIPG and rGBM studies should be the key upcoming catalysts for the stock, in our opinion."

Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com)